Premium
New treatments for type 2 diabetes: are we any closer to reducing iatrogenic hypoglycaemia?
Author(s) -
Seewoodhary Jason,
Wong Stephen Phooi Yew,
Ekanayake Kaharanthilaka Poojanie
Publication year - 2015
Publication title -
practical diabetes
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.205
H-Index - 24
eISSN - 2047-2900
pISSN - 2047-2897
DOI - 10.1002/pdi.1977
Subject(s) - medicine , diabetes mellitus , type 2 diabetes , intensive care medicine , type 1 diabetes , iatrogenic disease , surgery , endocrinology
The barrier of iatrogenic hypoglycaemia has limited the utility and safety of conventional diabetes medications. Novel agents for type 2 diabetes aim to surmount the impediment of iatrogenic hypoglycaemia and unmask the full realisation and benefits of achieving sustained euglycaemia over a lifetime of diabetes. This review aims to critically consider the risk of iatrogenic hypoglycaemia allied with newer agents for type 2 diabetes, used alone and in combination with other diabetes therapies, and how this risk can be minimised. Copyright © 2015 John Wiley & Sons. Copyright © 2015 John Wiley & Sons, Ltd.